You are currently viewing the abstract.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
Register for free to read this article
As a service to the community, this article is available for free. Existing users log in.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Abstract
The identification of “driver mutations” in cancers initiated rapid development of targeted drugs for the clinic. Despite promising outcomes initially in patients, the ultimate success of oncogene-targeted drugs has been hampered by the redundancy and remarkable complexity of cellular signaling pathways. Two studies in Science Signaling show that understanding these intricate networks and considering them during tumor classification and drug design can better predict drug response. These studies exemplify the potential of using systems analysis and computational modeling approaches to improve therapeutic strategies and outcomes in cancer patients.